Pascal Paubel

462 total citations
55 papers, 302 citations indexed

About

Pascal Paubel is a scholar working on Economics and Econometrics, Immunology and General Health Professions. According to data from OpenAlex, Pascal Paubel has authored 55 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Economics and Econometrics, 13 papers in Immunology and 9 papers in General Health Professions. Recurrent topics in Pascal Paubel's work include Health Systems, Economic Evaluations, Quality of Life (26 papers), Pharmaceutical Economics and Policy (24 papers) and Biosimilars and Bioanalytical Methods (13 papers). Pascal Paubel is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (26 papers), Pharmaceutical Economics and Policy (24 papers) and Biosimilars and Bioanalytical Methods (13 papers). Pascal Paubel collaborates with scholars based in France, Canada and Australia. Pascal Paubel's co-authors include Marie‐Liesse Piketty, Claude Le Pen, François C. Bocquet, Francine Chassoux, Elisabeth Landré, Kelley Kaye, Yves Contejean, Catherine Doyen, Jean‐Pierre Lotz and M. Ribault and has published in prestigious journals such as Transfusion, Journal of Chromatography B and Value in Health.

In The Last Decade

Pascal Paubel

40 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pascal Paubel France 10 110 85 74 68 39 55 302
AF Cohen Netherlands 11 18 0.2× 90 1.1× 56 0.8× 30 0.4× 99 2.5× 15 444
Ingrid Klingmann Germany 12 104 0.9× 65 0.8× 16 0.2× 17 0.3× 10 0.3× 43 452
Robert Cho United States 8 12 0.1× 27 0.3× 22 0.3× 29 0.4× 50 1.3× 12 270
Marietta Anthony United States 10 33 0.3× 55 0.6× 33 0.4× 5 0.1× 30 0.8× 15 368
J. B. M. J. Jansen Netherlands 16 26 0.2× 12 0.1× 31 0.4× 52 0.8× 25 0.6× 36 657
Julie Eve Desmarais Canada 11 69 0.6× 65 0.8× 132 1.8× 4 0.1× 81 2.1× 12 406
Lily Lai United Kingdom 9 28 0.3× 85 1.0× 29 0.4× 24 0.4× 28 0.7× 26 645
W. E. Dodson United States 8 35 0.3× 192 2.3× 158 2.1× 4 0.1× 35 0.9× 15 310
Danny Soon Singapore 11 5 0.0× 47 0.6× 43 0.6× 25 0.4× 43 1.1× 24 425
T. R. Browne United States 15 35 0.3× 363 4.3× 384 5.2× 5 0.1× 40 1.0× 21 603

Countries citing papers authored by Pascal Paubel

Since Specialization
Citations

This map shows the geographic impact of Pascal Paubel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Paubel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Paubel more than expected).

Fields of papers citing papers by Pascal Paubel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Paubel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Paubel. The network helps show where Pascal Paubel may publish in the future.

Co-authorship network of co-authors of Pascal Paubel

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Paubel. A scholar is included among the top collaborators of Pascal Paubel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Paubel. Pascal Paubel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hug, Martin J., et al.. (2023). Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry: A Cross-Country Comparison of List Prices and Purchase Prices. Applied Health Economics and Health Policy. 21(6). 905–914. 3 indexed citations
2.
Paubel, Pascal, et al.. (2023). What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France. Applied Health Economics and Health Policy. 21(5). 799–811. 8 indexed citations
3.
Lasocki, Sigismond, David Fuks, P.-H. Savoie, et al.. (2023). Management of perioperative iron deficiency anemia as part of patient blood management in France: A budget impact model‐based analysis based on real world data. Transfusion. 63(9). 1692–1700. 3 indexed citations
4.
Paubel, Pascal, et al.. (2021). Les médicaments hybrides en France. Genèse des médicaments hybrides et cadre règlementaire en Europe et en France. Annales Pharmaceutiques Françaises. 79(6). 609–616.
5.
Cohen, Jean-David, et al.. (2020). Preconceived notions about biosimilars—a French experience. Clinical Rheumatology. 39(8). 2251–2254.
6.
7.
8.
Tabchouri, Nicolas, Christine Denet, Jean‐Marc Ferraz, et al.. (2018). Enhanced recovery protocols in colonic surgery: retrospective cohort analysis of economic impact from an institutional point of view. International Journal of Colorectal Disease. 34(2). 301–307. 3 indexed citations
9.
Paubel, Pascal, et al.. (2016). First monoclonal antibody biosimilars: tackling the challenge of substitution. Journal of Medical Economics. 19(6). 645–647. 6 indexed citations
10.
11.
Renet, Sophie, et al.. (2016). Parcours de soins : modélisation et analyse des risques induits par les anticancéreux oraux. Bulletin du Cancer. 103(4). 345–352. 11 indexed citations
12.
Bocquet, François C., et al.. (2015). Defibrotide in Veno-Occlusive Disease in Public Hospitals of Paris: Funding Issues and Perspectives. Value in Health. 18(7). A518–A518. 1 indexed citations
13.
Paubel, Pascal, et al.. (2015). Economic Impact of The End of The Market Exclusivity for Orphan Drugs. Value in Health. 18(7). A678–A678. 1 indexed citations
14.
Bocquet, François C., et al.. (2015). Budget Impact Analysis of Implementing Tenders Between The Branded Infliximab And Its Biosimilars In The Public Hospitals of Paris. Value in Health. 18(7). A639–A639. 3 indexed citations
15.
Paubel, Pascal, et al.. (2014). Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis. Applied Health Economics and Health Policy. 12(3). 315–26. 17 indexed citations
16.
17.
18.
Paubel, Pascal, et al.. (2009). Correcteurs des troubles neurologiques des antipsychotiques : analyse de la prescription. Journal de Pharmacie Clinique. 28(2). 65–72.
19.
Contejean, Yves, et al.. (2008). Traitement d’un enfant autiste par la naltrexone. L Encéphale. 35(2). 168–172. 5 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by AF Cohen Breakdown of academic impact, for papers by Ingrid Klingmann Breakdown of academic impact, for papers by Robert Cho Breakdown of academic impact, for papers by Marietta Anthony Breakdown of academic impact, for papers by J. B. M. J. Jansen Breakdown of academic impact, for papers by Julie Eve Desmarais Breakdown of academic impact, for papers by Lily Lai Breakdown of academic impact, for papers by W. E. Dodson Breakdown of academic impact, for papers by Danny Soon Breakdown of academic impact, for papers by T. R. Browne
Rankless by CCL
2026